Researchers published late-stage clinical trial data for retatrutide, showing patients on the highest dose lost an average of 25% of body weight after 80 weeks and 30% after 104 weeks. The drug also demonstrated significant improvements in obesity-related conditions including knee osteoarthritis pain, sleep apnea, and prediabetes resolution.
Background
Retatrutide is a triple-hormone receptor agonist currently in late-stage clinical development as an obesity treatment. The results represent one of the most significant advances in weight-loss medication, potentially surpassing existing GLP-1 drugs like semaglutide.
- Source
- Ars Technica
- Published
- Sep 30, 2026 at 06:30 AM
- Score
- 9.0 / 10